A healthcare worker helps a senior man using a walker

The SOaR2 program: Returning patients to their families and enhancing survival in spinal metastases

An evolving and growing initiative, SOaR2 has the objective of advancing the early discovery and treatment of spinal metastases.

  • July 17, 2025

A multidisciplinary team has introduced a program with the objective of advancing the early discovery and treatment of spinal metastases (SMs).

The decades-old, constantly evolving, and growing initiative, named SOaR2, is composed of four key components: Surgical spinal oncology, medical oncology, radiation oncology, and neuroradiology.

The impact of delay in spinal metastases (SM) discovery and treatment

The spine is the most common site for metastases from primary cancers, particularly those originating in the breast, prostate, and lung.

Left untreated, SMs are a source of pain, vertebral fractures, and radiculopathy.

Perhaps the greatest clinical concern for malignant invasion of the spine is metastatic spinal cord compression (MSCC), a debilitating oncological emergency with the potential to provoke irreversible neurological deficits, loss of function, and morbidity. 

Unchecked MSCC has a far more profound impact on quality of life and survival than the original cancer diagnosis. MSCC can be effectively treated if spinal metastases are identified early, but this is possible only with timely recognition and treatment.

Recent studies of referral patterns suggest that delays in MSCC diagnosis and treatment occur in gaps in clinical communication, which occur in the time between:

  • Onset of symptoms and medical consultation (often at an ER)
  • Medical consultation and diagnosis
  • Diagnosis and referral to a spine surgeon
  • Referral to the spine surgeon/radiation oncologist and surgical treatment or radiation therapy

The same studies suggest that the average time between the onset of complaints and initiation of comprehensive treatment ranges from 11 to 14 weeks.

The SOaR2 program seeks to initiate treatment with immediacy and compress the entire treatment course to 6-8 weeks.

SOAR: Time to spine

The stated goal of the SOaR2 program is to provide the right interventions at the right time for the right patients to hasten their return to their communities and lives. This is achieved by streamlining the spinal oncology referral process from the outset through multidisciplinary group collaboration to reduce time to consultation and treatment, enhance patient navigation, and prioritize scheduling.

A chief benefit of the SOaR2 program is that all care takes place within a single uniform system.

The success of the SOaR2 program is evidenced in its recorded capacity to return patients to the community in 6-8 weeks from onset of symptoms (this may include imaging, biopsy, multi-disciplinary tumor board, evaluation, surgery, and post-operative radiation).

SOaR2 protocols and pathways

The leading advantage of early intervention in spinal metastases is avoidance of the destructive progression of MSCC.

Moreover, early diagnosis and consensus on care can prompt neurological improvement, a return to ambulation, and, for many patients, restoration to working life (BMC Palliative Care, March 2018).

To expedite the diagnosis and treatment of spinal metastases, the SOaR2 program eliminates delays from the outset to abbreviate gaps and delays in the patient journey:

Success of the SOaR2 program

The SOaR2 program has seen significant growth with multi-disciplinary consultations increasing from 87 to 122 (140%) over the last year. Patients treated with spine SBRT increased from 112 to 178 (159%), and total treatment sessions from 272 to 512 (188%).

Case report

Mrs. R, a 46-year-old woman with a history of breast cancer, was referred to Penn Orthopaedic Oncology for evaluation of a femur lesion.

Mrs. R was also referred to SOaR2 program radiation oncologist Anish Butala, MD, a specialist in spinal oncology, who discovered a previously undetected high-risk lesion at T9 on her CT simulation scan, requiring urgent evaluation .

Three days later, a rapid MRI confirmed Mrs. R’s T9 disease. This was followed the next day by a spinal biopsy, which was reviewed the same day at the multidisciplinary spine tumor board meeting.

Mrs. R was then referred to neurosurgeon Neil Malhotra, MD, who performed a T9 laminectomy and bilateral transpedicular corpectomy with a T7-11 fusion to ablate the tumor and address consequent instability in the spine.

Mrs. R then had post-operative stereotactic radiotherapy for a total of three treatments over six days. In the subsequent weeks, she had no significant side effects from her SBRT aside from mild temporary fatigue and nausea, and had no incisional issues. Penn Medicine Home Health provided access to at-home occupational and physical therapy and nursing.

Mrs. R’s total time from imaging to completion of treatment for her T9 lesion comprised 52 days (7 weeks, 3 days), which included a 12-day pause to accommodate her concomitant femur surgery.

About the SOaR2 Program

At Penn Medicine, the SOaR2 Program has brought together experts in surgical spinal oncology, medical oncology, and radiation oncology for over a decade with the goal of improving spinal tumor outcomes and reducing spinal cord metastases.

Our goal is to provide the right interventions at the right time for the right patients so they can return to their communities and lives faster. We do this by streamlining the spinal oncology process from the beginning, involving a collaborative multidisciplinary group and priority scheduling.

Program Leadership Team

The SOaR2 program is led by six leaders encompassing the key specialties that patients most need when cancer spreads to the spine.

Clinical consult and patient referral

Referrals into the SOaR2 Program can be made directly through program leads Anish Butala, MD, and Neil R. Malhotra, MD.

  • For hospital transfers and urgent clinical consults, call 877-937-7366, press 1. For non-urgent clinical consults and patient referrals, press 2 or visit PennMedicine.org/Refer.

Follow us

Related articles

Physician updates straight to your inbox

Subscribe to receive the latest clinical updates and news for physicians—including research highlights, case reports, and expert perspectives.